NUVB Nuvation Bio Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%
Returns
ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $44.95M | $31.69M | $83.23M | $41.87M | $13.12M | $4.83M | $3.08M | $5.71M |
| Cost of revenue | — | — | — | — | $3.35M | $2.58M | $2.09M | $4.22M |
| Gross profit | — | — | — | — | $9.77M | $2.26M | $990,000 | $1.50M |
| R&D expense | $32.68M | $30.66M | $35.05M | $34.30M | $28.85M | $27.36M | $24.60M | $29.30M |
| SG&A expense | $42.55M | $42.59M | $38.31M | $40.33M | $37.36M | $38.48M | $35.39M | $26.14M |
| Operating income | -$42.21M | -$51.04M | $3.88M | -$34.04M | -$56.43M | -$63.59M | -$59.00M | -$53.94M |
| Interest expense | $881,000 | $6.76M | $6.71M | $6.67M | $5.12M | $421,000 | $54,000 | $89,000 |
| Pretax income | -$41.90M | -$62.84M | $5.40M | -$36.59M | -$55.79M | -$59.01M | -$53.24M | -$49.45M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$41.90M | -$62.84M | $5.40M | -$36.59M | -$55.79M | -$59.01M | -$53.24M | -$49.45M |
| EBITDA | -$41.63M | -$50.50M | $4.42M | -$33.50M | -$55.90M | -$63.23M | -$58.69M | -$53.72M |
| EPS (basic) | -0.12 | -0.18 | 0.02 | — | -0.16 | -0.17 | -0.16 | — |
| EPS (diluted) | -0.12 | -0.18 | 0.01 | — | -0.16 | -0.17 | -0.16 | — |
| Weighted avg. shares (diluted) | 351,861 | 348,770 | 377,521 | — | 342,393 | 340,746 | 338,612 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $153.77M | $258.60M | $125.39M | $164.09M | $98.90M | $247.97M | $47.98M | $35.72M |
| Short-term investments | $509.60M | $402.35M | $408.34M | $365.12M | $450.15M | $359.75M | $413.70M | $466.97M |
| Inventory | $15.34M | $19.90M | $15.84M | $11.41M | $5.71M | $552,000 | $14,000 | $0 |
| Current assets | $734.66M | $726.43M | $591.53M | $571.52M | $577.53M | $623.21M | $475.57M | $526.25M |
| PP&E, net | $2.22M | $715,000 | $535,000 | $564,000 | $560,000 | $615,000 | $562,000 | $586,000 |
| Intangibles | $19.80M | $10.29M | $10.76M | $11.21M | $11.68M | $12.14M | $4.41M | $4.62M |
| Total assets | $778.39M | $744.50M | $610.24M | $594.82M | $601.56M | $647.23M | $492.49M | $540.63M |
| Current liabilities | $98.56M | $86.75M | $79.52M | $82.23M | $68.13M | $66.36M | $52.77M | $58.24M |
| Short-term debt | $5.97M | $5.89M | $5.79M | $5.72M | $5.62M | $5.58M | $5.68M | $6.28M |
| Long-term debt | $279.46M | $242.62M | $47.33M | $47.21M | $47.09M | $46.97M | — | — |
| Total debt | $285.43M | $248.52M | $53.12M | $52.93M | $52.71M | $52.56M | — | — |
| Total liabilities | $550.42M | $490.64M | $290.68M | $289.11M | $275.68M | $274.32M | $73.03M | $76.84M |
| Shareholders' equity | $227.97M | $253.86M | $319.56M | $305.72M | $325.88M | $372.91M | $419.46M | $463.79M |
| Net debt | $131.66M | -$10.09M | -$72.27M | -$111.15M | -$46.19M | -$195.41M | — | — |
| Shares outstanding | 346.50M | 346.50M | 346.50M | 346.50M | 337.84M | 337.84M | 337.84M | 337.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$38.56M | -$42.97M | $5.07M | -$29.73M | -$52.89M | -$48.18M | -$42.63M | -$46.30M |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$29.73M | — | — | — | -$46.30M |
| Investing cash flow | -$109.34M | $5.99M | -$43.64M | $87.08M | -$96.62M | $54.88M | $54.18M | $51.77M |
| Financing cash flow | $43.16M | $170.53M | $44,000 | $8.06M | $501,000 | $193.42M | $548,000 | -$900,000 |
| Depreciation & amortization | $578,000 | $536,000 | $536,000 | $539,000 | $534,000 | $356,000 | $310,000 | $219,000 |
| Stock-based compensation | $10.07M | $10.46M | $9.03M | $7.99M | $8.02M | $12.03M | $7.85M | $10.19M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.